Efficiency and safety of laser photocoagulation with or without intravitreal ranibizumab for treatment of diabetic macular edema: a systematic review and Meta-analysis

被引:5
|
作者
Tian-Wei Qian [1 ,2 ]
Meng-Ya Zhao [1 ,2 ]
Xin-Xin Li [1 ,2 ]
Xun Xu [1 ,2 ]
机构
[1] Department of Ophthalmology,Shanghai General Hospital
[2] Shanghai Key Laboratory of Ocular Fundus Diseases
基金
中国国家自然科学基金;
关键词
ranibizumab; diabetic macular edema; laser therapy; anti-vascular endothelial growth factor; Meta-analysis;
D O I
暂无
中图分类号
R587.2 [糖尿病性昏迷及其他并发症]; R774.5 [黄斑、中心窝疾病];
学科分类号
1002 ; 100201 ; 100212 ;
摘要
AIM: To compare the therapeutic effect and safety of laser photocoagulation along with intravitreal ranibizumab(IVR) versus laser therapy in treatment of diabetic macular edema(DME).METHODS: Pertinent publications were identified through comprehensive searches of Pub Med, EMBASE, Web of Science, Cochrane Library, and Clinical Trials.gov to identify randomized clinical trials(RCTs) comparing IVR+laser to laser monotherapy in patients with DME. Therapeutic effect estimates were determined by weighted mean differences(WMD) of change from baseline in best corrected visual acuity(BCVA) and central retinal thickness(CRT) at 6, 12, or 24 mo after initial treatment, and the risk ratios(RR) for the proportions of patients with at least 10 letters of improvement or reduction at 12 mo. Data regarding major ocular and nonocular adverse events(AEs) were collected and analyzed. The Review Manager 5.3.5 was used.RESULTS: Six RCTs involving 2069 patients with DME were selected for this Meta-analysis. The results showed that IVR+laser significantly improved BCVA compared with laser at 6mo(WMD: 6.57; 95% CI: 4.37-8.77; P<0.00001), 12mo(WMD: 5.46; 95% CI: 4.35-6.58; P<0.00001), and 24mo(WMD: 3.42; 95% CI: 0.84-5.99; P=0.009) in patients with DME. IVR+laser was superior to laser in reducing CRT at 12 mo from baseline with statistical significance(WMD:-63.46; 95% CI:-101.19 to-25.73; P=0.001). The pooled RR results showed that the proportions of patients with at least 10 letters of improvement or reduction were in favor of IVR+laser arms compared with laser(RR: 2.13; 95% CI: 1.77-2.57; P<0.00001 and RR: 0.37; 95% CI: 0.22-0.62; P=0.0002, respectively). As for AEs, the pooled results showed that a significantly higher proportion ofpatients suffering from conjunctival hemorrhage(study eye) and diabetic retinal edema(fellow eye) in IVR+laser group compared to laser group(RR: 3.29; 95% CI: 1.53-7.09; P=0.002 and RR: 3.02; 95% CI: 1.24-7.32; P=0.01, respectively). The incidence of other ocular and nonocular AEs considered in this Meta-analysis had no statistical difference between IVR+laser and laser alone.CONCLUSION: The results of our analysis show that IVR+laser has better availability in functional(improving BCVA) and anatomic(reducing CRT) outcomes than laser monotherapy for the treatment of DME. However, the patients who received the treatment of IVR+laser may get a higher risk of suffering from conjunctival hemorrhage(study eye) and diabetic retinal edema(fellow eye).
引用
收藏
页码:1134 / 1143
页数:10
相关论文
共 50 条
  • [31] The effect and safety of intravitreal injection of ranibizumab and bevacizumab on the corneal endothelium in the treatment of diabetic macular edema
    Guzel, Huseyin
    Bakbak, Berker
    Koylu, Mehmet Talay
    Gonul, Saban
    Ozturk, Banu
    Gedik, Sansal
    CUTANEOUS AND OCULAR TOXICOLOGY, 2017, 36 (01) : 5 - 8
  • [32] Effectiveness of intravitreal ranibizumab for diabetic macular edema in vitrectomized versus non-vitrectomized eyes: a Meta-analysis
    Wang, Yi-Heng
    Xu, Qian
    Luan, Jie
    INTERNATIONAL JOURNAL OF OPHTHALMOLOGY, 2024, 17 (04) : 729 - 735
  • [33] Topical bromfenac as adjunctive treatment with intravitreal ranibizumab for diabetic macular edema
    Gabr, Ahmed F.
    Kamel, Marian F.
    Elbarawy, Ahmed A.
    INTERNATIONAL OPHTHALMOLOGY, 2023, 43 (09) : 3219 - 3226
  • [34] Topical bromfenac as adjunctive treatment with intravitreal ranibizumab for diabetic macular edema
    Ahmed F. Gabr
    Marian F. Kamel
    Ahmed A. Elbarawy
    International Ophthalmology, 2023, 43 : 3219 - 3226
  • [35] PARS PLANA VITRECTOMY FOR DIABETIC MACULAR EDEMA A Systematic Review, Meta-Analysis, and Synthesis of Safety Literature
    Jackson, Timothy L.
    Nicod, Elena
    Angelis, Aris
    Grimaccia, Federico
    Pringle, Edward
    Kanavos, Panos
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2017, 37 (05): : 886 - 895
  • [36] Comparison of Intravitreal Triamcinolone Acetonide with Intravitreal Bevacizumab for Treatment of Diabetic Macular Edema: A Meta-analysis
    Zhang, Yue
    Ma, Jinlan
    Meng, Nana
    Li, Hao
    Qu, Yi
    CURRENT EYE RESEARCH, 2013, 38 (05) : 578 - 587
  • [37] The efficacy and safety of combined methotrexate with anti-vascular endothelial growth factor therapy in treatment of diabetic macular edema A protocol for systematic review and meta-analysis
    Bao, Yuzhi
    Lu, Xiaolei
    Zhou, Yuwei
    MEDICINE, 2021, 100 (19) : E25684
  • [38] Comparison of Natural Course, Intravitreal Triamcinolone and Macular laser photocoagulation for Treatment of Mild Diabetic Macular Edema
    Kwon, Soon Il
    Baek, Sung Uk
    Park, In Won
    INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 2013, 10 (03): : 243 - 249
  • [39] Macular laser photocoagulation with or without intravitreal triamcinolone pretreatment for diabetic macular edema: a result from five randomized controlled trials
    Liu, Xiang-Dong
    Zhou, Xiao-Dong
    Wang, Zhi
    Shen, Yong-Ming
    INTERNATIONAL JOURNAL OF OPHTHALMOLOGY, 2016, 9 (01) : 132 - 138
  • [40] Intravitreal bevacizumab with or without triamcinolone acetonide for diabetic macular edema: a meta-analysis of randomized controlled trials
    Liu Xiangdong
    Zhou Xiaodong
    Wang Zhi
    Li Tao
    Jiang Bo
    CHINESE MEDICAL JOURNAL, 2014, 127 (19) : 3471 - 3476